Spatial heterogeneity of MRI response to first-line hormonal therapy to predict progression-free survival in metastatic breast cancer.

被引：0
|
作者：
Kosmin, Michael
Makris, Andreas
Sokhi, Heminder
Thijssen, Toon
Padhani, Anwar R.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Acad Oncol Unit, Pinner, England
[3] Paul Strickland Scanner Ctr, Northwood, Middx, England
[4] Paul Strickland Scanner Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12544
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12544
引用
收藏
页数：6
相关论文
共 50 条
  • [21] KRAS mutation status to predict response in first-line capox and bevacizumab therapy for metastatic colorectal cancer.
    Yone, You
    Abdallah, Mohammad
    Tahir, Saad Sabih
    Cellek, Selim
    Zhang, Jufen
    Lester, Yvonne
    Shillito, Lauren
    Child, Jennifer
    Dawson, Lizzie
    Singizi, Bryan
    Bustin, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [22] DESCRIPTIVE STUDY OF METASTATIC BREAST CANCER PATIENTS WITH LONG-TERM PROGRESSION-FREE SURVIVAL DURING FIRST-LINE HORMONE THERAPY: EXPERIENCE FROM A SINGLE CANCER CENTER
    Illarramendi, Jose Juan
    Salgado, Esteban
    Lainez, Nuria
    Vicente, Francisco
    Cordoba, Alicia
    Vera, Ruth
    BREAST, 2011, 20 : S42 - S43
  • [23] Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer (vol 27, pg 3611, 2009)
    Gradishar
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : 2739 - 2739
  • [24] Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
    Bartlett, Cynthia Huang
    Mardekian, Jack
    Cotter, Matthew James
    Huang, Xin
    Zhang, Zhe
    Parrinello, Christina M.
    Bourla, Ariel Bulua
    PLOS ONE, 2020, 15 (04):
  • [25] Tesetaxel, an Oral Taxane, as First-Line Therapy for Women with Metastatic Breast Cancer.
    Schwartzberg, L.
    Rubin, P.
    Patnaik, A.
    Itri, L.
    Olson, A. L.
    Seidman, A. D.
    CANCER RESEARCH, 2011, 71
  • [26] PROGRESSION-FREE SURVIVAL AND POSTPROGRESSION SURVIVAL IN PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH FIRST-LINE CHEMOTHERAPY
    Shitara, K.
    Matsuo, K.
    Muro, K.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 232 - 232
  • [27] Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy
    Shitara, Kohei
    Matsuo, Keitaro
    Muro, Kei
    Doi, Toshihiko
    Ohtsu, Atsushi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (08) : 1383 - 1389
  • [28] Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy
    Kohei Shitara
    Keitaro Matsuo
    Kei Muro
    Toshihiko Doi
    Atsushi Ohtsu
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1383 - 1389
  • [29] Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC
    Rutkowski, Jacek
    Saad, Everardo D.
    Burzykowski, Tomasz
    Buyse, Marc
    Jassem, Jacek
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1619 - 1627
  • [30] Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
    Beauchemin, Catherine
    Cooper, Dan
    Lapierre, Marie-Eve
    Yelle, Louise
    Lachaine, Jean
    ONCOTARGETS AND THERAPY, 2014, 7 : 1101 - 1110
12345